Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic AZN
Time: 14:37:27
Mid Price: 2833.00
Change Today: 53.00 Ascending
Change % Today: 1.91 Ascending
Fifty Two Week High: 3102.50
Fifty Two Week Low: 2147.00
Market Capital: 41156.10
Period & price data
Period Price
Now: 2833.00
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
Epic: AZN
News: Latest news
Web Site: AstraZeneca
Other Articles: 07-01-201016-12-200904-12-2009

AstraZeneca

AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.

Sales in 2007 totalled $29.6 billion, with an operating profit of $9 billion

Thursday, November 19, 2009

AstraZeneca Applies To the FDA For Its New Angina and Heart Attack Treatment

company news image

AstraZenec (LSE: AZN) announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the drug ticagrelo. The application is for an investigational oral antiplatelet treatment for patients with acute coronary syndrome (ACS).


 The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA. According to AstraZeneca, Ticagrelor is the first reversibly binding oral P2Y12 adenosine diphosphate (ADP) receptor antagonist. The drug inhibits the action of platelets in the blood to prevent platelets from sticking together, thereby reducing recurrent thrombotic events.


Acute coronary syndrome (ACS) is an umbrella term for conditions that result from a reduction in blood flow to the heart muscle, including unstable angina and heart attacks. According to the American Heart Association (AHA), ACS affects an estimated 1.4 million people in the US every year. The AHA says that it is estimated that one third of ACS patients will have another episode within six months of the first cardiovascular event, often leading to hospitalisation, another heart attack or the patients death.


The submission to the FDA is based on the results of a comprehensive programme, it includes data from PLATO (A Study of Platelet Inhibition and Patient Outcomes) and the Phase III trial comparing ticagrelor plus aspirin with Sanofi Aventis’ Plavix®, clopidogrel plus aspirin.

NewsNow icon AddThis Feed Button
Register here to be notified of future AstraZeneca articles.

Other AstraZeneca articles

More articles ►

Other AstraZeneca news

More news ►

Investors interested in AstraZeneca recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.